Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE
Launched by LUCID DIAGNOSTICS, INC. · Feb 29, 2020
Trial Information
Current as of July 08, 2025
Completed
Keywords
ClinConnect Summary
This is a multicenter, single-arm study designed to assess the operating characteristics of the EsoGuard diagnostic assay performed on distal esophageal mucosal cells collected using the EsoCheck cell collection device, compared to the gold standard, for the screening of BE with and without dysplasia and for esophageal adenocarcinoma (EAC), in patients at high risk for BE and for whom a screening EGD is indicated according to ACG-established criteria.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Men aged 50 years old and older
- • 2. ≥5 years either of
- • GERD symptoms,
- • GERD treated with proton pump inhibitor (PPI) therapy (whether symptom control is achieved or not), or,
- • any combination of treated and untreated periods, as long the cumulative total is at least 5 years
- • 3. No solid foods eaten for at least 2 hours prior to EsoCheck procedure
- 4. One or more of the following risk factors:
- • 1. Caucasian race
- • 2. Current or past history of cigarette smoking
- • 3. BMI of at least 30 kg/m2
- • 4. First-degree relative with BE or EAC
- • -
- Exclusion Criteria:
- • 1. History of prior EGD procedure
- • 2. Inability to provide written informed consent
- • 3. On anti-coagulant drug(s) that cannot be temporarily discontinued
- • 4. Known history of esophageal varices or esophageal stricture
- • 5. Any contraindication, as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and/or having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and/or esophageal ulceration
- • 6. History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills
- • 7. Oropharyngeal tumor
- • 8. History of esophageal or gastric surgery, with exception of uncomplicated surgical fundoplication procedure
- • 9. History of myocardial infarction or cerebrovascular accident within past 6 months
- • 10. History of esophageal motility disorder
- • 11. Currently implanted Linx device
About Lucid Diagnostics, Inc.
Lucid Diagnostics, Inc. is a pioneering medical technology company focused on transforming the early detection and monitoring of gastrointestinal diseases. With a commitment to advancing patient care, Lucid develops innovative diagnostic solutions that leverage cutting-edge technology and evidence-based research. Their flagship product, a non-invasive test for dysplasia and esophageal cancer, exemplifies the company’s dedication to improving clinical outcomes and enhancing patient quality of life. Through ongoing clinical trials and partnerships, Lucid Diagnostics aims to expand its portfolio of diagnostic tools and contribute to the advancement of precision medicine in gastroenterology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Orange, California, United States
Englewood, Colorado, United States
Jacksonville, Florida, United States
Naples, Florida, United States
Palm Harbor, Florida, United States
Macon, Georgia, United States
Idaho Falls, Idaho, United States
Rockford, Illinois, United States
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
Wyoming, Michigan, United States
Flowood, Mississippi, United States
Omaha, Nebraska, United States
New York, New York, United States
Rochester, New York, United States
Chapel Hill, North Carolina, United States
Oklahoma City, Oklahoma, United States
Philadelphia, Pennsylvania, United States
Providence, Rhode Island, United States
Greenville, South Carolina, United States
Knoxville, Tennessee, United States
Nashville, Tennessee, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Richmond, Virginia, United States
Bellevue, Washington, United States
Madrid, , Spain
Valladolid, , Spain
Zaragoza, , Spain
Patients applied
Trial Officials
Michelle McDermott
Study Director
Lucid Diagnostics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials